Identification of a functional mutation in pp32r1 (ANP32C)

G. John Kochevar, Jonathan R. Brody, ShriHari S. Kadkol, Kathleen M. Murphy, Gary R. Pasternack

Research output: Contribution to journalArticle

Abstract

No mutations or polymorphisms have previously been reported in pp32r1 (ANP32C; GenBank: AF008216.1). pp32r1 is part of the highly conserved ANP32 family, some of whose members are associated with control of histone acetylation, mRNA stability, and specialized forms of apoptosis. Although 87.6% identical at the protein level, pp32r1 is functionally distinct from pp32 (ANP32A) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays. The present study found that pp32r1 expression levels vary among human tumor cell lines, with the highest levels found in prostatic adenocarcinoma cell lines. pp32r1 also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions, human fibroblast cell lines, and several carcinoma cell lines. PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci, but additionally contain a g.4870T>C transversion mutation. The mutation results in a p.Tyr140His substitution, which lies in a functionally important region of the molecule. In the PC-3 prostate cancer line, the mutation is either homozygous, or hemizygous accompanied by loss of heterozygosity. ACHN cells stably transfected with pp32r1 containing this mutation showed a markedly increased rate of growth. The pp32r1 mutation could thus be causally associated with the neoplastic growth properties of PC-3, and be of potential clinical significance.

Original languageEnglish (US)
Pages (from-to)546-551
Number of pages6
JournalHuman Mutation
Volume23
Issue number6
DOIs
StatePublished - May 2004

Fingerprint

Mutation
Cell Line
Adenocarcinoma
Nucleotides
Smokeless Tobacco
Loss of Heterozygosity
Nucleic Acid Databases
RNA Stability
Acetylation
Growth
Tumor Cell Line
Histones
Prostatic Neoplasms
Carcinogenesis
Fibroblasts
Apoptosis
Carcinoma
Proteins

Keywords

  • ANP32C
  • Cancer
  • Mutation
  • PC
  • pp32
  • pp32r1
  • Proliferation
  • Prostate cancer

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Kochevar, G. J., Brody, J. R., Kadkol, S. S., Murphy, K. M., & Pasternack, G. R. (2004). Identification of a functional mutation in pp32r1 (ANP32C). Human Mutation, 23(6), 546-551. https://doi.org/10.1002/humu.20030

Identification of a functional mutation in pp32r1 (ANP32C). / Kochevar, G. John; Brody, Jonathan R.; Kadkol, ShriHari S.; Murphy, Kathleen M.; Pasternack, Gary R.

In: Human Mutation, Vol. 23, No. 6, 05.2004, p. 546-551.

Research output: Contribution to journalArticle

Kochevar, GJ, Brody, JR, Kadkol, SS, Murphy, KM & Pasternack, GR 2004, 'Identification of a functional mutation in pp32r1 (ANP32C)', Human Mutation, vol. 23, no. 6, pp. 546-551. https://doi.org/10.1002/humu.20030
Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR. Identification of a functional mutation in pp32r1 (ANP32C). Human Mutation. 2004 May;23(6):546-551. https://doi.org/10.1002/humu.20030
Kochevar, G. John ; Brody, Jonathan R. ; Kadkol, ShriHari S. ; Murphy, Kathleen M. ; Pasternack, Gary R. / Identification of a functional mutation in pp32r1 (ANP32C). In: Human Mutation. 2004 ; Vol. 23, No. 6. pp. 546-551.
@article{be50a4f8465d45bca4c0cbd3a2cd5e02,
title = "Identification of a functional mutation in pp32r1 (ANP32C)",
abstract = "No mutations or polymorphisms have previously been reported in pp32r1 (ANP32C; GenBank: AF008216.1). pp32r1 is part of the highly conserved ANP32 family, some of whose members are associated with control of histone acetylation, mRNA stability, and specialized forms of apoptosis. Although 87.6{\%} identical at the protein level, pp32r1 is functionally distinct from pp32 (ANP32A) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays. The present study found that pp32r1 expression levels vary among human tumor cell lines, with the highest levels found in prostatic adenocarcinoma cell lines. pp32r1 also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions, human fibroblast cell lines, and several carcinoma cell lines. PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci, but additionally contain a g.4870T>C transversion mutation. The mutation results in a p.Tyr140His substitution, which lies in a functionally important region of the molecule. In the PC-3 prostate cancer line, the mutation is either homozygous, or hemizygous accompanied by loss of heterozygosity. ACHN cells stably transfected with pp32r1 containing this mutation showed a markedly increased rate of growth. The pp32r1 mutation could thus be causally associated with the neoplastic growth properties of PC-3, and be of potential clinical significance.",
keywords = "ANP32C, Cancer, Mutation, PC, pp32, pp32r1, Proliferation, Prostate cancer",
author = "Kochevar, {G. John} and Brody, {Jonathan R.} and Kadkol, {ShriHari S.} and Murphy, {Kathleen M.} and Pasternack, {Gary R.}",
year = "2004",
month = "5",
doi = "10.1002/humu.20030",
language = "English (US)",
volume = "23",
pages = "546--551",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Identification of a functional mutation in pp32r1 (ANP32C)

AU - Kochevar, G. John

AU - Brody, Jonathan R.

AU - Kadkol, ShriHari S.

AU - Murphy, Kathleen M.

AU - Pasternack, Gary R.

PY - 2004/5

Y1 - 2004/5

N2 - No mutations or polymorphisms have previously been reported in pp32r1 (ANP32C; GenBank: AF008216.1). pp32r1 is part of the highly conserved ANP32 family, some of whose members are associated with control of histone acetylation, mRNA stability, and specialized forms of apoptosis. Although 87.6% identical at the protein level, pp32r1 is functionally distinct from pp32 (ANP32A) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays. The present study found that pp32r1 expression levels vary among human tumor cell lines, with the highest levels found in prostatic adenocarcinoma cell lines. pp32r1 also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions, human fibroblast cell lines, and several carcinoma cell lines. PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci, but additionally contain a g.4870T>C transversion mutation. The mutation results in a p.Tyr140His substitution, which lies in a functionally important region of the molecule. In the PC-3 prostate cancer line, the mutation is either homozygous, or hemizygous accompanied by loss of heterozygosity. ACHN cells stably transfected with pp32r1 containing this mutation showed a markedly increased rate of growth. The pp32r1 mutation could thus be causally associated with the neoplastic growth properties of PC-3, and be of potential clinical significance.

AB - No mutations or polymorphisms have previously been reported in pp32r1 (ANP32C; GenBank: AF008216.1). pp32r1 is part of the highly conserved ANP32 family, some of whose members are associated with control of histone acetylation, mRNA stability, and specialized forms of apoptosis. Although 87.6% identical at the protein level, pp32r1 is functionally distinct from pp32 (ANP32A) in its failure to suppress oncogenesis in in vitro transformation systems and its tumorigenicity in in vivo assays. The present study found that pp32r1 expression levels vary among human tumor cell lines, with the highest levels found in prostatic adenocarcinoma cell lines. pp32r1 also appears to be polymorphic at nucleotide g.4520 and nucleotide g.4664 in human tobacco-associated oral mucosal lesions, human fibroblast cell lines, and several carcinoma cell lines. PC-3 human prostatic adenocarcinoma cells likewise appear to be polymorphic at these loci, but additionally contain a g.4870T>C transversion mutation. The mutation results in a p.Tyr140His substitution, which lies in a functionally important region of the molecule. In the PC-3 prostate cancer line, the mutation is either homozygous, or hemizygous accompanied by loss of heterozygosity. ACHN cells stably transfected with pp32r1 containing this mutation showed a markedly increased rate of growth. The pp32r1 mutation could thus be causally associated with the neoplastic growth properties of PC-3, and be of potential clinical significance.

KW - ANP32C

KW - Cancer

KW - Mutation

KW - PC

KW - pp32

KW - pp32r1

KW - Proliferation

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=2642512486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642512486&partnerID=8YFLogxK

U2 - 10.1002/humu.20030

DO - 10.1002/humu.20030

M3 - Article

C2 - 15146458

AN - SCOPUS:2642512486

VL - 23

SP - 546

EP - 551

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 6

ER -